Even as our understanding of nontuberculous mycobacterial (NTM) lung disease advances, major gaps remain, from defining meaningful treatment success to overcoming innate drug resistance. In this conversation with Dr. Alexandria May, Dr. David Griffith shares his perspective on how recent evidence is shaping treatment decisions for these patients and explains why significant unmet needs persist. Dr. Griffith is a Professor of Medicine in the Division of Mycobacterial and Respiratory Infections within the Department of Medicine at National Jewish Health in Denver.